Cop 1 for treatment of inflammatory bowel diseases

Details Cop 1 for treatment of inflammatory bowel diseases Cop 1 for treatment of inflammatory bowel diseases

2011-08-30

2011-08-30

Bradley, Christina (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C514S001100

Reexamination Certificate

active

08008258

ABSTRACT:
The present invention relates to the use of Copolymer 1 (glatiramer acetate), a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide, for the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.

REFERENCES:
patent: 5800808 (1998-09-01), Konfino et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 5981589 (1999-11-01), Konfino et al.
patent: 6048898 (2000-04-01), Konfino et al.
patent: 6054430 (2000-04-01), Konfino et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: 6362161 (2002-03-01), Konfino et al.
patent: 6620847 (2003-09-01), Konfino et al.
patent: 6939539 (2005-09-01), Konfino et al.
patent: 7199098 (2007-04-01), Konfino et al.
patent: 2002/0055466 (2002-05-01), Aharoni et al.
patent: 2005/0171286 (2005-08-01), Konfino et al.
patent: 2006/0122113 (2006-06-01), Pinchasi et al.
patent: 2007/0021341 (2007-01-01), Sela et al.
patent: 2007/0117757 (2007-05-01), Konfino et al.
patent: WO 00/05249 (2000-02-01), None
patent: WO 00/05250 (2000-02-01), None
patent: 0018794 (2000-04-01), None
patent: WO 00/20010 (2000-04-01), None
patent: WO 00/27417 (2000-05-01), None
patent: WO 01/60392 (2001-08-01), None
Aharoni et al. “Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis” Proc. Natl. Acad. Sci., 1997, 94, 10821-6.
Shanahan “Inflammatory Bowel Disease: Immunotherapeutics, Immunodiagnostics, and Ecotherapeutics” Gastroenterology, 2001, 120, 622-35.
Rogler & Andus “Cytokines in Inflammatory Bowel Disease” World J. of Surg., 1998, 22, 382-9.
Aharoni et al. “Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1” J. Neuroimmunology, 1998, 91, 135-46.
Neuhaus et al. “Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells” Proc. Natl. Acad. Sci., 2000, 97, 7452-7.
Swain “Blister packaging leads the way” Pharmaceutical and Medical Packaging News Magazine, 1999, pp. 1-4.
FDA Label for COPAXONE (Copolymer-1) Jul. 12, 2001.
U.S. Appl. No. 11/516,860, filed Sep. 6, 2006, Gad et al.
U.S. Appl. No. 11/528,894, filed Sep. 27, 2006, Aharoni et al.
U.S. Appl. No. 11/541,263, filed Sep. 29, 2006, Pinchasi et al.
U.S. Appl. No. 11/590,338, filed Oct. 30, 2006, Pinchasi et al.
Teitelbaum D., Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis,Proc. Natl. Acad. Sci. U.S.A.,Sep. 1997, 94(20), 10821-10826.
Sandborn W.J. (2005) “State-of-the-Art: Targeting Immunoregulation—Biologicals,”Inflammatory Bowel Disease Translation from Basic Research to Clinical Practice,Falk Symposium 140, pp. 90-97.
Vandenbroucke K, et al. (2010) “Orally AdministeredL. lactisSecreting an Anti-TNF Nanobody Demonstrate Efficacy in Chronic Colitis,”Mucosal Immunol.3(1):pp. 49-56 (Abstract Only).
Ashizuka S, et al. (2009) “Adrenomedullin Treatment Reduces Intestinal Inflammation and Maintains Epithelial Barrier Function in Mice Administered Dextran Sulphate Sodium,”Microbol Immunol.53(10): pp. 573-581 (Abstract Only).
Chen G, et al. (2010) “Blockade of Complement Activation Product C5a Activity Using Specific Antibody Attenuates Intestinal Damage in Trinitrobenzene Sulfonic Acid Induced Model of Colitis,”Lab Invest.[Epub ahead of print] (Abstract Only).
Nishitani Yosuke, (2009) “Lactococcus lacticSubsp. Cremoris FC Alleviates Symptoms of Colitis Induced by Dextran Sulfate Sodium in Mice,”International Immunopharmacology,9 : pp. 1444-1451.
Mileti Erika, et al. (2009) “Comparison of the Immunomodulatory Properties of Three Probiotic Strains of Lactobacilli Using Complex Culture Systems: Prediction for In Vivo Efficacy,”PLoS ONE4(9): e7056.
Bai Aiping, et al. (2010) “Novel Anti-Inflammatory Action of 5-Aminoimidazole-4-carboxamide Ribonucleoside with Protective Effect in Dextran Sulfate Sodium-Induced Acute and Chronic Colitis,”The Journal of Pharmocology and Experimental Therapeutics,333: pp. 717-725.
Bai Aiping, et al. (2009) “All-Trans Retinoic Acid Down-Regulates Inflammatory Responses by Shifting the Treg/Th17 Profile in Human Ulcerative and Murine Colitis,”Journal of Leukocyte Biology,86: pp. 959-969.
Srinivasan Mythily and Summerlin Don-Jon (2009), “Modulation of the Colonic Epithelial Cell Responses and Amelioration and Inflammation by CD80 Blockade in TNBS Colitis,”Clinical Immunology,133: pp. 411-421.
Bai Aiping, et al. (2010) “AMPK Agonist Downregulates Innate and Adaptive Immune Responses in TNBS-induced Murine,”Biochemical Pharmacology,80: pp. 1708-1717.
Danese S. and Angelucci E. (2009) “New and Emerging Biologics in the Treatment of Inflammatory Bowel Disease: Quo Vadis?”Gastroenterol Clin Biol.,33 Suppl 3: pp. S217-S227.
Ng SC, et al. (2010) “Review Article: The Role of Non-Biological Drugs in Refractory Inflammatory Bowel Disease,”Aliment Pharmacol Ther.[Epub ahead of print] (Abstract Only).
Buruiana FE, et al. (2010) “Recombinant Human Interleukin 10 for Induction of Remission in Crohn's Disease,”Cochrane Database Syst Rev.11:CD005109 (Abstract Only).
Yoshida Eric, M. (1999), “The Crohn's Disease Activity Index, Its Derivatives and the Inflammatory Bowel Disease Questionnaire: A Review of Instruments to Assess Crohn's Disease,”Can J Gastroenterol,13(1): pp. 65-73.
Ashizuka Shinya, et al. (2009), “Adrenomedullin Treatment Reduces Intestinal Inflammation and Maintains Epithelial Barrier Function in Mice Administered Dextran Sulphate Sodium,”Microbiol Immunol,53: pp. 573-581.
Billerey-Larmonier Claire (2008), “Protective Effects of Dietary Curcumin in Mouse Model of Chemically Induced Colitis Are Strain Dependent,”Inflamm Bowel Dis,14(6): pp. 780-793.
Buruiana FE, et al. (2010), “Recombinant Human Interleukin 10 for Induction of Remission in Crohn's Disease (Review),”Cochrane Database of Systematic Review 2010,11: pp. 1-22.
Chen Guojiang, et al. (2010), “Blockade of Complement Activation Product C5a Activity Using Specific Antibody Attenuates Intestinal Damage in Trinitrobenzene Sulfonic Acid Induced Model of Colitis,”Laboratory Investigation,pp. 1-12.
Danese S. and Angelucci E. (2009), “New and Emerging Biologics in the Treatment of Inflammatory Bowel Disease: Quo Vadis? Quelles Biotherapies pour Demain dans les Maladies Inflammatoires Chroniques Intestinales?”Gastroenterologie Clinique et Biologique,33 (3) : pp. S217-S227.
Elson Charles, O., et al. (1995), “Experimental Models of Inflammatory Bowel Disease,”Gastroenterology,109: pp. 1344-1367.
Harvey R.F. and Bradshaw J.M. (1980), “A Simple Index of Crohn's-Disease Activity,”The Lancet,p. 514.
Sostegni R., et al. (2003), “Review Article: Crohn's Disease: Monitoring Disease Activity,”Aliment Pharmacol Ther,17(2): pp. 11-17.
Neurath Markus, E., et al. (1995), “Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in Mice,”The Journal of Experimental Medicine,182: pp. 1281-1290.
Ng S.C., et al. (2010), Review Article: The Role of Non-Biological Drugs in Refractory Inflammatory Bowel Disease,Aliment Pharamcol Ther,pp. 1-11.
Parkes M. and Jewell D.P. (2001), “Review Article: The Management of Severe Crohn's Disease,”Aliment Pharmacol Ther,15: pp. 563-573.
Strober Warren, et al. (2002), “The Immunology of Mucosal Models of Inflammation,”Annu. Rev. Immunol.,20: pp. 495-549.
Vandenbroucke K., et al. (2010), “Orally AdministeredL. lactisSecreting an Anti-TNF Nanobody Demonstrate Efficacy in Chronic Colitis,”Mucosal Immunology,3(

Affiliated with

Also associated with

Rating

Cop 1 for treatment of inflammatory bowel diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cop 1 for treatment of inflammatory bowel diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cop 1 for treatment of inflammatory bowel diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2775063